Apatinib End-of-Phase 2 meeting scheduled with US FDA
LSKB has scheduled an End-of-Phase 2 meeting with US FDA on July 20, 2016 to discuss clinical development plans for apatinib. The FDA guidance from this meeting will assist LSKB in finalizing the design of a pivotal Phase 3 study in patients with gastric cancer and review other studies intended to support FDA and other marketing applications. The Company will provide further information on apatinib clinical development plans after the meeting.
